Navigation Links
TIBCO Speeds Drug Discovery for Chemists
Date:11/11/2008

TIBCO Spotfire Lead Discovery provides an easy-to-use, highly visual and interactive environment for exploring chemical structures and any associated data

SOMERVILLE, Mass., Nov. 11 /PRNewswire-FirstCall/ -- TIBCO Software Inc. (Nasdaq: TIBX), today announced the release of TIBCO Spotfire(R) Lead Discovery. The solution allows chemists to quickly access chemistry and biological data in a single analysis environment, then easily build best-practice applications for chemical structure analysis. The solution, built on the powerful TIBCO Spotfire(R) Enterprise Analytics platform, integrates with leading cheminformatics software, including Symyx and CambridgeSoft.

In order to determine which compounds to synthesize to optimize the drug discovery and development process, chemists must evaluate an increasing number of parameters - from chemical properties and biological assays to absorption and excretion (ADME) results. Spotfire(R) Lead Discovery offers intuitive data representations and best practice analytics processes that any chemist can use to quickly ask and answer their own questions of their data.

"Spotfire Lead Discovery enhances a chemist's intuition and expertise in deciphering complex problems and driving faster, more efficient drug discovery, enabling them to work more flexibly with the disparate technologies and data sources used in analysis today," said Christian Marcazzo, senior director, Industry Solutions Life Sciences, Spotfire Division of TIBCO Software Inc.

Visual, Interactive Analysis Helps Chemists Focus on Scientific Questions Instead of Software

With TIBCO Spotfire(R), chemists can visualize and explore relationships between chemistry and biological data - as well as other relevant information - from a single application. Medicinal chemists and computational chemists can investigate and drive structural recommendations more quickly and thoroughly, improving the process for choosing synthesis paths for effective drug design. To jump-start analysis, the software includes a range of the best practice applications for lead discovery, including:

-- Library analysis

-- Structure activity relationship analysis

-- Selectivity analysis

-- Compound series analysis.

"Dynamic querying capabilities, stunning visualization, and a highly interactive and flexible interface have made TIBCO Spotfire the industry standard within the life sciences industry," added Marcazzo. "This solution raises the bar by helping chemists focus on making fast, well-informed decisions by investigating all the relevant data in a single, interactive environment that speeds insights and encourages further discovery."

TIBCO Spotfire Lead Discovery provides the ability to:

-- Visually interact with 3-D scatter plots, profile charts, pie charts,

bar charts, and histograms, while filtering data via range sliders,

check boxes, radio buttons, or search.

-- Represent complex datasets and quickly identify relationships between

structures, calculated or measured properties, and biological assay

results.

-- Manage and compare unlimited number of chemical structures.

-- Integrate with a variety of chemical databases and structure-searching

capabilities

-- Share analysis, workflow, and decision points with key collaborators in

a common analysis environment.

-- Load chemical data from chemical cartridges and SD files

About TIBCO

TIBCO Software Inc. (Nasdaq: TIBX) is a leading provider of enterprise analytics software for next generation business intelligence. TIBCO Spotfire products offer a visual and interactive experience that helps professionals quickly discover new and actionable insights in information. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value. Spotfire customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit http://spotfire.tibco.com.

TIBCO, TIBCO Software, TIBCO Spotfire, TIBCO Spotfire Enterprise Analytics, and TIBCO Spotfire Lead Discovery are trademarks or registered trademarks of TIBCO Software Inc. or its subsidiaries in the United States and/or other countries. All other product and company names and marks mentioned in this document are the property of their respective owners and are mentioned for identification purposes only.

Media Inquiries:

Amy Groden-Morrison Jim Baptiste

TIBCO Software Inc. Davies Murphy Group

617-702-1710 781-418-2438

amorriso@tibco.com jbaptiste@daviesmurphy.com

http://spotfire.tibco.com http://daviesmurphy.com


'/>"/>
SOURCE TIBCO Software Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. TIBCO Spotfire and Integromics Partner on Development of Genomics Platform for Province of Andalusia
2. TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech
3. TIBCO Spotfire and INTEGROMICS Announce Genomics Data Analysis Solution to Radically Speed Drug Research and Development
4. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. European Centre for Modern Drug Discovery Established in Hamburg
7. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
8. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
9. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
10. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
11. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):